TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

Clinical trial NCT06487663 · RECRUITING

Trial details

NCT number: NCT06487663
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Non-resectable Cholangiocarcinoma Non-resectable Liver Metastases Liver Malignant Tumors

Start date: 2020-10-27
Primary completion: 2025-10-27
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.